We measured bone mineral density (BMD) with dualenergy X-ray absorptiometry in the total body, at the lumbar spine, at the femoral neck and in the total hip, in 18 young adults with a median of 18.2 years after SCT. Fifteen patients had undergone auto-SCT and all patients had received TBI. The patients had significantly lower BMD in the total body, at the femoral neck, and in the total hip compared with age-and sex-matched controls. Six of 18 patients (33%) had low bone mass (z-score oÀ1) at one or more measurement sites, as opposed to two of the controls (11%, P ¼ 0.29). We found no significant influence of growth hormone levels or of untreated hypogonadism on BMD variables. Levels of 25-hydroxy (25(OH)) vitamin D were lower among the patients (35.2 vs 48.8 nmol/L, P ¼ 0.044) and were significantly correlated with total body BMD in the patient group (r ¼ 0.55, P ¼ 0.021). All six patients with low bone mass had hypovitaminosis D (p37 nmol/L as opposed to 4 of the 11 (36%) patients without low bone mass (P ¼ 0.035). In conclusion, we found decreased BMD in SCT survivors, which may in part be caused by 25(OH) vitamin D deficiency.
Introduction
Bone mineral acquisition may be disturbed by a number of factors in patients treated with TBI-based SCT during childhood and adolescence. Superimposed on previous cancer treatment, these factors include the direct effects on the bone and the effects of impaired growth hormone (GH) and sex hormone secretion. 1, 2 In addition, after allo-SCT chronic GVHD (cGVHD) may ensue, entailing long-term glucocorticoid and CYA treatment. [3] [4] [5] SCT survivors are often underweight and may be prone to physical inactivity. 6, 7 Furthermore, low levels of 25-hydroxy (25(OH)) vitamin D have been documented in long-term adult survivors, but only in the short term after SCT in childhood. [8] [9] [10] Decreased bone mineral density (BMD) has been reported after childhood SCT, but there are few long-term studies and consequently a limited number of patients who have been studied after attaining peak bone mass. 5, [11] [12] [13] [14] The aim of the present study was to investigate the long-term effects of TBI-based SCT on BMD in a group of young adults and to explore potential risk factors for reduced BMD. Most patients had undergone auto-SCT and none had experienced cGVHD.
Patients and methods
We aimed to investigate BMD in long-term transplant survivors (defined here as being alive more than 10 years after SCT) treated with TBI for ALL or lymphoblastic lymphoma (these malignancies were treated similarly). Between the start of the pediatric SCT program at Uppsala University Children's Hospital from October 1985 to June 1999 (that is, 10 years before the conclusion of the present study in June 2009), 45 children under 18 years of age, and one patient who was 18.3 years, with ALL (n ¼ 43) or lymphoblastic lymphoma (n ¼ 3) were treated with auto-(n ¼ 31), syngeneic (n ¼ 1) or allo-(n ¼ 14) SCT including TBI. Of these, 29 are alive today (autologous/syngeneic, n ¼ 22, allogeneic, n ¼ 7). Eligible for this study were those who had undergone auto-SCT or allo-SCT without cGVHD. They should also have reached final height (annual increase in height less than 1 cm during the preceding year). A total of 25 patients fulfilled these criteria and were subsequently invited to participate (autologous/ syngeneic, n ¼ 22, allogeneic, n ¼ 3). One female and six male invitees declined participation in the study, resulting in a study group of 15 autografted patients and three recipients of an allogeneic graft (Table 1) . Only one female patient cited a late complication as cause for nonparticipation (pending surgery for a meningioma). One patient was a smoker (15 cigarettes/day). One girl developed idiopathic pneumonia syndrome 6 weeks after SCT.
Corticosteroid therapy had a prompt effect on the symptoms and was tapered over a period of 5 months. Otherwise, no patient received long-term corticosteroids.
The patients had been treated according to the leukemia protocol that applied at the time of diagnosis. 15 Seven patients had received cranial radiation therapy of 18-26 Gy (median 24 Gy), including the spine in a girl with central nervous system relapse, and three males had received radiation to the testes (16, 21 and 32 Gy, respectively). Details of the conditioning regimen have been presented elsewhere. 16 Briefly, patients were conditioned with a CY-based chemotherapy regimen plus TBI, given in most children (n ¼ 12) as a single fraction of 7.5 Gy on day À1 as two opposed 5 MV X-ray anterior-posterior fields with lung shielding. The six patients most recently undergoing transplantation were treated with fractionated TBI, consisting of 12.6 Gy in six fractions over 3 days. GVHD prophylaxis consisted of short-term MTX, and of CYA, which was tapered over 6 months.
Endocrine treatment during puberty until attainment of final height Twelve patients underwent SCT before the start of puberty. No patient had delayed puberty, defined as the onset of puberty after the age of 13 years in girls and 14 years in boys.
Details of the endocrinological treatment during puberty after SCT at our center have been presented elsewhere. 17 Puberty was induced in two girls using increasing doses of ethinylestradiol at the ages of 11.3 and 12.4 years, respectively. One girl was given a low dose of ethinylestradiol from 10.6 years of age until menarche was achieved at the age of 12.8 years. Puberty was induced at the age of 13.9 years in the boy who received additional testicular radiation of 32 Gy. The other two boys who received additional testicular radiation developed hypergonadotrophic hypogonadism later and received androgen treatment at the ages of 15.4 and 16.4 years, respectively. Nine patients received GH treatment (median 3.6 years, range 2.0 to 4.8 years), which was discontinued after achieving final height. One female was started on GH treatment 2 years after SCT and was still receiving treatment at the time of the study. Nine patients with subclinical hypothyroidism received thyroxine substitution and were still receiving treatment at the time of the study.
Control participants
In order to select one age-and sex-matched control participant for each patient, letters were sent to 10 potential control subjects for each patient. The controls were selected randomly from a computerized register of the population of Uppsala County. Of those who accepted by mail, the first who replied to a phone call and was deemed eligible for the study was chosen, provided that they did not meet any of the exclusion criteria (known disease, medication other than contraceptives, current pregnancy, smoker). If none of the 10 selected control subjects agreed to participate, a new set of 10 controls was selected and the process was repeated (Table 1) .
Study protocol
Standing height and weight were measured in the morning. S.d. scores for height were calculated, using a Swedish reference according to the formula (actual heightÀmean height for age and sex)/s.d. of height for age and sex. 18 Body mass index was calculated as body mass in kilograms divided by the height in meters squared (kg/m 2 ). Dual energy X-ray Absorptiometry (DXA, Lunar Radiation, Madison, WI, USA) was used to measure body fat mass and areal BMD of the total body, lumbar spine, total hip (left side reported here), and femoral neck (left side reported here). BMDs were transformed into z-scores by comparing the measured values with age-specific and sexspecific data as provided by the manufacturer. Serum samples for thyroxin, follicle stimulating hormone, luteinizing hormone, estradiol, testosterone, calcium, ionized calcium, phosphate, magnesium, alanine transaminase, 25(OH) vitamin D, osteocalcin and beta-crosslaps (crosslinked telopeptide of type I collagen) were collected in the morning after a 12-h overnight fast. 25(OH) vitamin D levels were assayed by chemoluminiscence (DiaSorin, Liaison, Saluggia, Italy). The assay measured both 25(OH) vitamin D 2 and 25(OH) vitamin D 3 . The analytical sensitivity was o2.5 nmol/L and the specificity was 104% for 25(OH) vitamin D 2 and 100% for 25(OH) vitamin D 3 . The intra-assay coefficients of variation (CV) for total 25(OH) vitamin D were 7.1 and 3.6% at levels of 44.7 and 120 nmol/L, respectively. For osteocalcin (Roche Cobas e601, Roche, Basel, Switzerland) the intra-assay CVs were 0.94 and 0.94% at levels of 20.5 and 184 mg/L, respectively. For beta-crosslaps (Roche Cobas e601) the intra-assay CVs were 1.84 and 1.44% at levels of 294 and 2868 ng/L, respectively. Spontaneous GH secretion was measured by sampling blood every 30 min during the night (12 h). The maximum peak value (GH peak) was compared between patients and controls. Data on GH and fat mass have been reported previously. 19 
Statistical analysis
Statistical comparisons between patients and controls are presented as median with the interquartile range within parentheses. We compared patients and controls with the Wilcoxon signed-rank test for matched pairs. Intragroup comparisons were made with the Mann-Whitney U-test. Comparisons of categorical variables between patients and controls were made with the McNemar test and intragroup comparisons with Fisher's exact test. The Spearman rank correlation coefficient was used for correlation analyses. Multiple regression analyses were performed to analyze the influence of different factors on BMD. Here, the natural (Table 2 , which also includes standardized z-scores) The male patients had significantly lower BMD total and BMD totalhip compared with the male controls, whereas there were no significant differences among the females. The patients were significantly shorter than the controls, whereas no differences were seen in body mass index or fat mass between the groups (Table 3 ). In multivariate analyses including sex, height (m), and patient/control-status, only patient status had an independent negative influence on BMD total (B ¼ À0.07, P ¼ 0.019), BMD femneck (B ¼ À0.12, P ¼ 0.037) and BMD totalhip (B ¼ À0.13, P ¼ 0.012), but not on BMD lumbar thus reflecting the results of the univariate analyses. Six of 18 patients (33%) had a low bone mass (BMD z-score less than À1) at one or more measurement sites, as opposed to 2 of 18 control subjects (11%, P ¼ 0.29). Levels of osteocalcin were significantly lower in the patients, but there was no difference in levels of betacrosslaps between the groups. (Table 3 ) Of investigated electrolytes, levels of phosphate were slightly lower in the patients. (Table 3) .
Endocrine treatment and status at the time of the study Four males and four females were receiving sex hormones/ anti-contraceptives. Untreated primary hypogonadism (testosterone o10 nmol/L or estradiol o100 pmol/L with concomitant supranormal gonadotrophin concentration) was documented in one male and in three females. Nine patients were receiving thyroxine substitution. All study subjects had normal thyroxine levels. One female was receiving GH. Levels of GH were significantly lower in the patients (excluding the patient with GH) (Table 3) . Low GH levels (o10 mU/L) were documented in 9 of 17 tested patients (53%) as opposed to 3 of 18 controls (17%, P ¼ 0.07). Levels of 25(OH) vitamin D were lower in the patients (Table 3 ). A total of 11 patients (61%) and 10 controls (56%) were tested during the period from October to March. There was a significant seasonal variation with lower 25(OH) vitamin D levels during the period from There was no difference in alanine transaminase between the patients and the controls (Table 3) . total into z-score (r ¼ 0.65, P ¼ 0.006). One female patient with a low bone mass had untreated primary hypogonadism. Two of six patients (33%) with low bone mass had low GH levels (o10 mU/L) as opposed to seven of eleven (64%) of those without low bone mass (P ¼ 0.34). All six patients with low bone mass had hypovitaminosis D (25(OH) vitamin D p37 nmol/L) as opposed to four of eleven (36%) of those without low bone mass (P ¼ 0.035). Also, 25(OH) vitamin D was significantly lower in the patients with low bone mass compared with those without (27 vs 40 nmol/L, P ¼ 0.007). Neither BMD total (r ¼ À0.12, P ¼ 0.64) nor levels of 25(OH) vitamin D (r ¼ 0.23, P ¼ 0.37) changed with regard to time after SCT.
Discussion
Decreased BMD has previously been reported after childhood SCT, but there are few long-term studies (45 years). 5, [11] [12] [13] [14] We present a study of areal BMD after SCT that constitutes the longest follow-up published to date (median 18.2 years) and in which all patients had reached final height. BMD total BMD femneck and BMD totalhip were significantly lower among the patients compared with the controls, but there was no significant difference in BMD lumbar This is consistent with data showing a preferential recovery of BMD in the lumbar spine after SCT. 20 However, as shown by Taskinen et al., a substantial number of SCT patients may have vertebral compression fractures (20% in their study), which may have an effect on the BMD results from the lumbar spine. 5 We also documented a low bone mass in 33% of long-term survivors, suggesting that one third of SCT patients are exposed to at least double the risk of future fractures. 21 This proportion was not significantly different from that of the controls (11%), however, probably due to the small number of study participants.
Most patients in the present study had undergone auto-SCT (15/18) for ALL, representing intensified cytotoxic treatment. In contrast with conventional ALL treatment, all patients had also received TBI, which might induce endocrine deficits, such as impaired GH secretion and hypogonadism in girls, and might also have direct effects on the BM stroma.
1,2 Jarfelt et al. 22 found a low bone mass in 10 of 35 young Swedish adult survivors (29%) with a median follow-up of 20 years after conventional ALL therapy, that is, a prevalence commensurate with that observed in our transplanted patients. On the other hand, 54% of their patients had received cranial radiation therapy, which might induce impaired GH secretion and short stature, compared with 39% in the present study. After allogenic SCT, cGHVD may cause further reduced BMD due to malabsorption and the need for long-term immunoppression. 3, 5 The three patients who underwent allo-SCT in the present study had no cGVHD. However, patients who have undergone allo-SCT might theoretically have lower BMD compared with auto-SCT even in the absence of cGVHD, as they have received post-SCT CYA (here tapered over 6 months). 4 Kananen et al. 8 found that in adult survivors after allo-SCT including TBI, BMD had recovered and bone turnover had normalized a median of 75 months after SCT compared with the situation 12 months after SCT, when CyA was tapered off. Also, in the only previous study of BMD in postpubertal survivors of childhood SCT, Taskinen et al.
14 reported on 16 patients aged 15-34 years after allo-SCT including TBI. They presented similar BMD findings to our predominantly autografted patients and a low bone mass was documented in 38% of their patients. In the long-term, the reductions in BMD and the prevalence of low bone mass thus appear to be little influenced by the SCT modality (autologous vs allogeneic) after discontinuation of immunosuppressive therapy. We believe that with time after SCT, the impact of immunosuppression wanes and other factors, such as endocrine deficits, become increasingly more important.
We found no correlation between BMD and levels of GH, which may be due to the fact that GH had been supplemented until final height in GH-deficient patients. 23 Four patients had untreated primary hypogonadism, one of whom had concomitant low bone mass. In contrast, levels of 25(OH) vitamin D were lower in the patient group and were positively correlated with BMD total both in univariate and multivariate analyses. Furthermore, hypovitaminosis D was significantly associated with low bone mass in the patient group. Even though decreased levels of 25(OH) vitamin D have been documented in adults after SCT, to our knowledge this is the first study to show this in longterm survivors after childhood SCT. 8, 9 In contrast, Daniels et al. 12 and Taskinen et al. 14 found no relationship between BMD and calciotropic hormones in survivors after childhood SCT. As production in the skin through UVB light exposure is an important source of vitamin D, one potential pitfall when interpreting vitamin D data is the seasonal variation with lower levels during winter at our latitudes. 24 In the present study, similar proportions of patients and controls were examined during the period from October to March. Another moot point is the definition of hypovitaminosis D and there is no absolute consensus as to what a normal range for 25(OH) vitamin D should be. 25 For the sake of comparison we chose the lower limit to be 37 nmol/L, which was used in two studies of BMD after SCT performed in Finland, and thus from similar latitudes to ours. 8, 14 The cause of decreased 25(OH) vitamin D in our patients is not readily apparent. 26 One possible explanation may be that SCT survivors are prone to a more sedentary lifestyle than their peers, including less outdoor activities and consequently less sun exposure. 7 Levels of outdoor activity were not recorded, hence this remains speculative. Other potential causes of low 25(OH) vitamin D after SCT include decreased synthesis due to liver dysfunction and decreased bioavailability due to malabsorption or increased body fat. Liver status, as assessed by alanine transaminase, did not differ between the patients and the controls in the The role of 25-hydroxyvitamin D P Frisk et al present study. Hypovitaminosis D has been described in SCT patients with intestinal cGVHD, but none of our patients experienced cGVHD. 27 Increased body fat may result in sequestration of 25(OH) vitamin D, but there was no significant difference in fat mass between patients and controls.
Height is positively associated with areal BMD and is commonly reduced after SCT. 17, 24, 28 In consequence, Nysom et al. 11 concluded that the slight decrease in BMD total documented in their SCT survivors was caused by reduced height alone. Surprisingly, Taskinen et al. In the present study, we found no independent influence of attained height on BMD.
There are several potential errors involved in the interpretation of data obtained from DXA studies. First, accurate reference data are crucial. Compared with the manufacturer's reference population, the patients' BMD z-scores were normal or only slightly decreased and those of the control group were consistently high. Interestingly, in a recent study from Uppsala, a Swedish female BMD reference representing peak bone mass was established from a population-based sample of 335 randomly selected women aged 20-39 years. 29 Notably, this cohort had considerably higher BMD (0.3-0.5 s.d.) as compared with both the manufacturer's reference populations as well as with the third National Health and Nutrition Examination Survey. 30 This underlines the importance of local controls and implies that the true prevalence of low bone mass could in fact be higher in the present study. We present BMD expressed as both g/cm 2 and as standardized z-scores based on the manufacturer's reference population. However, conclusions are based only on the former variable in analyzes between the groups and within the patient group. Furthermore, DXA does not reflect real density but the ratio of bone mineral content over an area, which may lead to an underestimation of BMD in patients with impaired growth. Quantitative computed tomography enables measurement of the 'true' BMD. Kaste et al. 13 measured vertebral BMD by quantitative computed tomography in 43 patients with a median of 5.1 years after allo-SCT in childhood and found that 11 patients had osteopenia and nine patients had osteoporosis (thus 47% had osteopenia or osteoporosis), that is, indeed higher prevalence numbers than in studies using areal BMD, including the present one. Another limitation of the present study is the rather small sample size, which restricts statistical power. The fact that 7 of 25 eligible survivors chose not to participate may also have introduced a selection bias. The strengths of our study are the comparatively homogeneous study population, the use of a locally enrolled matched control group and the long follow-up.
In conclusion, we found low bone mass in one third of our young adult patients, suggesting that a significant proportion of patients will not reach optimal peak bone mass after childhood SCT and will be at increased risk for future fractures. This underlines the importance of minimizing bone loss after SCT. As emphazised by the present study, it appears important to optimize nutritional intake of vitamin D. Therapy also includes treatment of SCTrelated sequelae that may exacerbate BMD deficits, such as GH deficiency and hypogonadism. In addition, physical activity, preferably weight-bearing activity, should be strongly encouraged. Patients should be screened annually with DXA as per the International Society of Clinical Densitometry guidelines and those presenting with osteoporosis or fractures should be considered for treatment with bisphosphonates.
